PDCD1 and non-small cell lung carcinoma: To our knowledge, this is the first prospective study to demonstrate that pituitary dysfunction and destructive thyroiditis are significantly associated with prolonged OS in NSCLC patients treated with anti-PD-1 antibodies, even after accounting for ITB, in real-world clinical practice.